RxDoctor Payments Data

Erin O'Connell

Family · Asheville, NCNPI 1104541598

Payments from drug & device makers

$2,141in general payments, 2019–2025

Across 126 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$456
  • AstraZeneca$283
  • Novo Nordisk$140
  • Lilly USA, LLC$133
  • Otsuka America Pharmaceutical, Inc.$130
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$119
  • plus $880 from 24 others

What the payments were for

  • Food & beverage$2,141100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,141 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$55,685
Medicare patients
152
Services billed
1,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$70,901
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$34,647
JardianceEmpagliflozin32$33,462
MounjaroTirzepatide18$22,928
EliquisApixaban22$22,158
VascepaIcosapent Ethyl24$13,645
TrulicityDulaglutide14$12,835
TradjentaLinagliptin15$11,914
Janumet XrSitagliptin Phos/Metformin Hcl15$11,286
FarxigaDapagliflozin Propanediol14$11,155
LinzessLinaclotide16$9,698
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$6,779
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$2,285
Ventolin HfaAlbuterol Sulfate16$1,493
Albuterol Sulfate HfaAlbuterol Sulfate41$1,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$140$70,90146 claims
Boehringer IngelheimJardiance, Tradjenta$17$45,37647 claims
GSKTrelegy Ellipta, Anoro Ellipta$97$41,42646 claims
Lilly USA, LLCMounjaro, Trulicity$133$35,76432 claims
PfizerEliquis$36$22,15822 claims
MerckJanumet Xr$45$11,28615 claims
AstraZenecaFarxiga$283$11,15514 claims
AbbVieLinzess$456$9,69816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.

Other family in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →